Patient and parent preferences for haemophilia A treatments

Haemophilia

Volumn 17, Issue 2, 2011, Pages 209-214

  Mohamed, A F ^a   Epstein, J D ^b   Li Mcleod, J M ^b  

^a RTI INTERNATIONAL   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Conjoint analysis; Discrete choice experiments; Factor VIII; Haemophilia A; Treatment preferences

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BLEEDING; BLOOD COMPONENT THERAPY; CHILD; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; HEALTH SURVEY; HEMOPHILIA A; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; PARENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PLASMA; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS INFECTION;

ADOLESCENT; ADULT; CHILD; CHOICE BEHAVIOR; FACTOR VIII; HEMOPHILIA A; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; YOUNG ADULT;

EID: 79951806675     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02411.x     Document Type: Article

References (29)

1. National Hemophilia Foundation. Fast facts. 2006. Available at: Accessed on November 17, 2008.
2. Grillberger L, Kreill TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009; 4: 186-201.
3. Peden A, McCardle L, Head MW et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
4. Sharp CP, Lail A, Donfield S et al. High frequencies of exposure to the novel human parvovirus PARV4 in haemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis 2009; 200: 1119-25.
5. Mannucci PM, Bonomi AB. The safety of plasma-derived versus recombinant concentrates. Occas Pap 2004; 5: 1-4.
6. Bridges JFP, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2008; 1: 273-82.
7. Louviere J, Swait J, Hensher D. Introduction to stated preference models and methods. In Louviere J, Swait J, Hensher D eds. Stated Choice Methods: Analysis and Application. Cambridge, UK: Cambridge University Press, 2000: 20-33.
8. Johnson FR, Ozdemir S, Mansfield C et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133: 769-79.
9. Johnson FR, Banzhaf M, Desvousges W. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format stated-preference approach. Health Econ 2000; 9: 295-317.
10. Ryan M, McIntosh E, Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Econ 1998; 7: 373-8.
11. Bryan S, Buxton M, Sheldon R, Grant A. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Econ 1998; 7: 595-603.
12. Ryan M, Gerard K. Discrete choice experiments. In: Fayers P, Hays R, (eds). Assessing Quality of Life in Clinical Trials: Methods and Practice: Second Edition. Oxford, UK: Oxford University Press, 2005: 431-45.
13. Hauber AB, Mohamed AF, Watson ME, Johnson FR, Hernandez JE. Benefits, risks, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments. AIDS Patient Care and STDs 2009; 23: 29-34.
14. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in haemophilia: genetics and environment. Semin Thromb Hemost 2009; 35: 723-4.
15. White GC, DiMichele D, Mertens K et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost 1999; 81: 462.
16. Lipkus IM, Hollands JG. The visual communication of risk. J Natl Cancer Inst Monogr 1999; 25: 149-63.
17. Krupnick A, Alberini A, Cropper M et al. Age, health and the willingness to pay for mortality risk reductions: a contingent valuation survey of Ontario residents. J Risk Uncertainty 2002; 24: 161-86.
18. Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Market Res 1996; 33: 307-17.
19. Kanninen B. Optimal design for multinomial choice experiments. J Market Res 2002; 39: 214-27.
20. Dey A. Orthogonal Fractional Factorial Designs. New York: Halstead Press, 1985.
21. Kuhfeld W, Tobias F, Garratt M. Efficient experimental design with marketing research applications. J Market Res 1994; 31: 545-57.
22. Zwerina K, Huber J, Kuhfeld W. A General Method for Constructing Efficient Choice Designs. Durham, NC: Fuqua School of Business, Duke University, 1996.
23. Train K. Discrete Choice Methods With Simulation. Cambridge: Cambridge University Press, 2003: 138-54.
24. Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A eds. Applications of Simulation Methods in Environmental and Resource Economics. Dordrecht: Springer Publisher, 2005: 117-34.
25. Hensher DA, Rose JM, Greene WH. Applied Choice Analysis. Cambridge: Cambridge University Press, 2005.
26. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients', physicians', and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11: 589-97.
27. Lee WC, Joshi AV, Woolford S et al. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia 2008; 14: 454-65.
28. Scalone L, Mantovani LG, Borghetti F, Von Mackensen S. Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA study. Haemophilia 2009; 15: 473-86.
29. Miller KL, Guelcher C, Taylor A. Haemophilia A: patients' knowledge level of treatment and sources of treatment-related information. Haemophilia 2009; 15: 73-7.